华东医药: 2024年半年度报告（英文版）内容摘要

（原标题：2024年半年度报告（英文版））

2024 Semi-Annual Report of Huadong Medicine Co., Ltd.

Current reporting period|Same period last year|Change of the current reporting period over the same period last year(%)| -|-|-|-| Operating revenue(yuan)|20,965,065,605.67|20,385,344,288.81|2.84%| Net profit attributable to shareholders of listed companies(yuan)|1,696,020,589.20|1,433,824,629.56|18.29%| Net profit attributable to shareholders of listed companies after deducting non-recurring gains/losses (yuan)|1,625,200,244.09|1,427,487,870.97|13.85%| Net cash flow from operating activities(yuan)|2,275,256,481.44|2,021,743,748.65|12.54%| Basic earnings per share (yuan/share)|0.9675|0.8194|18.07%| Diluted earnings per share (yuan/share)|0.9686|0.8190|18.27%| Weighted average return on equity(ROE)|7.80%|7.43%|0.37%|

End of the current reporting period|End of last year|Change of the end of the current reporting period over the end of last year(%)| -|-|-|-| Total assets(yuan)|36,166,783,775.64|33,509,361,816.98|7.93%| Net assets attributable to shareholders of listed companies(yuan)|21,760,294,487.74|21,047,609,756.66|3.39%|